Century Therapeutics (IPSC) Net Margin (2022 - 2025)
Historic Net Margin for Century Therapeutics (IPSC) over the last 4 years, with Q1 2025 value amounting to 70.13%.
- Century Therapeutics' Net Margin rose 33522400.0% to 70.13% in Q1 2025 from the same period last year, while for Sep 2025 it was 23.36%, marking a year-over-year increase of 48144800.0%. This contributed to the annual value of 1920.87% for FY2024, which is 41943900.0% up from last year.
- Per Century Therapeutics' latest filing, its Net Margin stood at 70.13% for Q1 2025, which was up 33522400.0% from 864.44% recorded in Q4 2024.
- In the past 5 years, Century Therapeutics' Net Margin ranged from a high of 70.13% in Q1 2025 and a low of 33627.27% during Q2 2023
- In the last 4 years, Century Therapeutics' Net Margin had a median value of 3545.65% in 2022 and averaged 7504.28%.
- As far as peak fluctuations go, Century Therapeutics' Net Margin tumbled by -314075000bps in 2023, and later surged by 295796700bps in 2024.
- Century Therapeutics' Net Margin (Quarter) stood at 6081.0% in 2022, then plummeted by -142bps to 14701.87% in 2023, then skyrocketed by 94bps to 864.44% in 2024, then soared by 108bps to 70.13% in 2025.
- Its Net Margin stands at 70.13% for Q1 2025, versus 864.44% for Q4 2024 and 3947.66% for Q3 2024.